8982 Federal Register / Vol. 75, No. 38 / Friday, February 26, 2010 / Notices 

‘‘Adenosine derivatives, method of 

synthesis thereof, and the 

pharmaceutical compositions for the 

prevention and treatment of the 

inflammatory diseases containing the 

same as an active ingredient,’’ filed 

March 7, 2007, [HHS Ref. No. E–109– 

2006/0–PCT–01] to Acorn Biomedical, 

Inc., having an office in at 612 SE. 5th 

Avenue, Suite #3, Fort Lauderdale, FL 

33301 U.S.A. The patent rights in these 

inventions have been assigned to the 

United States of America. 

The prospective exclusive license 

territory may be worldwide, and the 

field of use may be limited to the use 

of adenosine A3 antagonists for 

treatment of glaucoma and intraocular 

pressure. 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before March 

29, 2010 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, comments, 

and other materials relating to the 

contemplated exclusive license should 

be directed to: Steven Standley, Ph.D., 

Licensing and Patenting Manager, Office 

of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, MD 

20852–3804; Telephone: (301) 435– 

4074; Facsimile: (301) 402–0220; E-mail: 

sstand@od.nih.gov. 

SUPPLEMENTARY INFORMATION: Adenosine 

a3 antagonists applied topically to the 

cornea have been shown to cause a 

reduction in intraocular pressure, which 

is a means of treating glaucoma. 

The invention relates to several 

structurally different pharmacophores 

that have been shown to antagonize 

adenosine a3 receptors. Molecules are to 

be tested to optimize for the treatment 

of glaucoma and intraocular pressure in 

humans. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR part 404.7. The 

prospective exclusive license may be 

granted unless within thirty (30) days 

from the date of this published notice, 

the NIH receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR part 404.7. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: February 16, 2010. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2010–3907 Filed 2–25–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–3224–N] 

Medicare Program; Request for 

Nominations for Members for the 

Medicare Evidence Development & 

Coverage Advisory Committee 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), HHS. 

ACTION: Notice. 

SUMMARY: This notice announces the 

request for nominations for 

consideration for membership on the 

Medicare Evidence Development & 

Coverage Advisory Committee 

(MEDCAC). Among other things, the 

MEDCAC advises the Secretary of the 

Department of Health and Human 

Services (the Secretary) and the 

Administrator of the Centers for 

Medicare & Medicaid Services, as 

requested by the Secretary, whether 

medical items and services are 

‘‘reasonable and necessary’’ and 

therefore eligible for coverage under 

Title XVIII of the Social Security Act. 

We are requesting nominations for 

both voting and nonvoting members to 

serve on the MEDCAC. Nominees are 

selected based upon their individual 

qualifications and not as representatives 

of professional associations or societies. 

We have a special interest in ensuring 

that the interests of both women and 

men, members of all racial and ethnic 

groups, and physically challenged 

individuals are adequately represented 

on the MEDCAC. Therefore, we 

encourage nominations of qualified 

candidates who can represent these 

interests. 

The MEDCAC reviews and evaluates 

medical literature, reviews technology 

assessments, and examines data and 

information on the effectiveness and 

appropriateness of medical items and 

services that are covered or eligible for 

coverage under Medicare. 

DATES: Nominations will be considered 

if postmarked by Monday, March 29, 

2010 and mailed to the address 

specified in the ADDRESSES section of 

this notice. 

ADDRESSES: You may mail nominations 

for membership to the following: 

Centers for Medicare & Medicaid 

Services, Office of Clinical Standards 

and Quality, Attention: Maria Ellis, 7500 

Security Boulevard, Mail Stop: C1–09– 

06, Baltimore, MD 21244–1850. 

FOR FURTHER INFORMATION CONTACT: 

Maria Ellis, Executive Secretary for 

MEDCAC, Centers for Medicare & 

Medicaid Services, Office of Clinical 

Standards and Quality, Coverage and 

Analysis Group, C1–09–06, 7500 

Security Boulevard, Baltimore, MD 

21244 or contact Ms. Ellis by phone 

(410–786–0309) or via e-mail at 

Maria.Ellis@cms.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

I. Background 

On December 14, 1998, we published 

a notice in the Federal Register (63 FR 

68780) announcing establishment of the 

Medicare Coverage Advisory Committee 

(MCAC). The Secretary signed the initial 

charter for the Medicare Coverage 

Advisory Committee on November 24, 

1998. On January 26, 2007 the Secretary 

published a notice in the Federal 

Register (72 FR 3853), changing the 

Committee’s name to the Medicare 

Evidence Development and Coverage 

Advisory Committee (MEDCAC). The 

charter for the committee was renewed 

by the Secretary and will terminate on 

November 24, 2010, unless renewed 

again by the Secretary. 

The MEDCAC is governed by 

provisions of the Federal Advisory 

Committee Act, Public Law 92–463, as 

amended (5 U.S.C. App. 2), which sets 

forth standards for the formulation and 

use of advisory committees, and is 

authorized by section 222 of the Public 

Health Service Act as amended (42 

U.S.C. 217A). 

The MEDCAC consists of a pool of 

100 appointed members including: 6 

patient advocates, who are standard 

voting members; and 6 representatives 

of industry interests, who are nonvoting 

members. Members are selected from 

among authorities in clinical medicine 

of all specialties, administrative 

medicine, public health, biologic and 

physical sciences, health care data and 

information management and analysis, 

patient advocacy, the economics of 

health care, medical ethics, and other 

related professions such as 

epidemiology and biostatistics, and 

methodology of trial design. 

The MEDCAC functions on a 

committee basis. The committee reviews 

and evaluates medical literature, 

reviews technology assessments, and 


sroberts on DSKD5P82C1PROD with NOTICES
Federal Register / Vol. 75, No. 38 / Friday, February 26, 2010 / Notices 8983 

examines data and information on the 

effectiveness and appropriateness of 

medical items and services that are 

covered or eligible for coverage under 

Medicare. The Committee works from 

an agenda provided by the Designated 

Federal Official that lists specific issues, 

and develops technical advice to assist 

us in determining reasonable and 

necessary applications of medical 

services and technology when we make 

national coverage decisions for 

Medicare. The Committee also advises 

CMS as part of Medicare’s ‘‘coverage 

with evidence development’’ activities. 

II. Provisions of the Notice 

As of June 2010, there will be 34 

terms of membership expiring, 1 of 

which is a nonvoting industry 

representative and 4 are voting patient 

advocates. 

Accordingly, we are requesting 

nominations for both voting and 

nonvoting members to serve on the 

MEDCAC. Nominees are selected based 

upon their individual qualifications and 

not as representatives of professional 

associations or societies. We have a 

special interest in ensuring that the 

interests of both women and men, 

members of all racial and ethnic groups, 

and physically challenged individuals 

are adequately represented on the 

MEDCAC. Therefore, we encourage 

nominations of qualified candidates 

from these groups. 

All nominations must be 

accompanied by curricula vitae. 

Nomination packages must be sent to 

Maria Ellis at the address listed in the 

ADDRESSES section of this notice. 

Nominees for voting membership must 

also have expertise and experience in 

one or more of the following fields: 

• Clinical medicine of all specialties 

• Administrative medicine 

• Public health 

• Patient advocacy 

• Biologic and physical sciences 

• Health care data and information 

management and analysis 

• The economics of health care 

• Medical ethics 

• Other related professions such as 

epidemiology and biostatistics, and 

methodology of clinical trial design 

We are looking for experts in a 

number of fields. Our most critical 

needs are for experts in hematology; 

genomics; end of life care; Bayesian 

statistics; clinical epidemiology; clinical 

trial methodology; knee, hip, and other 

joint replacement surgery; 

ophthalmology; psychopharmacology; 

registries; rheumatology; screening and 

diagnostic testing analysis; and stroke. 

We also need experts in biostatistics in 

clinical settings, cardiovascular 

epidemiology, cost effectiveness 

analysis, dementia, endocrinology, 

geriatrics, gynecology, minority health, 

observational research design, stroke 

epidemiology, and women’s health. 

The nomination letter must include a 

statement that the nominee is willing to 

serve as a member of the MEDCAC and 

appears to have no conflict of interest 

that would preclude membership. We 

are requesting that all curricula vitae 

include the following: 

• Date of birth 

• Place of birth 

• Social security number 

• Title and current position 

• Professional affiliation 

• Home and business address 

• Telephone and fax numbers 

• E-mail address 

• List of areas of expertise 

In the nomination letter, we are 

requesting that the nominee specify 

whether they are applying for a voting 

patient advocate position, for another 

voting position, or as a nonvoting 

industry representative. Potential 

candidates will be asked to provide 

detailed information concerning such 

matters as financial holdings, 

consultancies, and research grants or 

contracts in order to permit evaluation 

of possible sources of conflict of 

interest. 

Members are invited to serve for 

overlapping 2-year terms. A member 

may serve after the expiration of the 

member’s term until a successor takes 

office. Any interested person may 

nominate one or more qualified persons. 

Self-nominations are also accepted. 

The current Secretary’s Charter for the 

MEDCAC is available on the CMS Web 

site at: http://www.cms.hhs.gov/FACA/ 

Downloads/medcaccharter.pdf, or you 

may obtain a copy of the charter by 

submitting a request to the contact listed 

in the FOR FURTHER INFORMATION section 

of this notice. 

Authority: 5 U.S.C. App. 2, section 

10(a)(1) and (a)(2). 

(Catalog of Federal Domestic Assistance 

Program No. 93.773, Medicare—Hospital 

Insurance; and Program No. 93.774, 

Medicare—Supplementary Medical 

Insurance Program) 

Dated: February 23, 2010. 

Barry M. Straube, 

CMS Chief Medical Officer, Director, Office 

of Clinical Standards and Quality, Centers 

for Medicare & Medicaid Services. 

[FR Doc. 2010–4019 Filed 2–25–10; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HOUSING AND 

URBAN DEVELOPMENT 

[Docket No. FR–5382–N–03] 

Notice of Proposed Information 

Collection for Public Comment: 

Housing Counseling Outcomes Study 

AGENCY: Office of Policy Development 

and Research, HUD. 

ACTION: Notice. 

SUMMARY: The proposed information 

collection requirement described below 

will be submitted to the Office of 

Management and Budget (OMB) for 

review, as required by the Paperwork 

Reduction Act. The Department is 

soliciting public comments on the 

subject proposal. 

DATES: Comments Due Date: April 27, 

2010. 

ADDRESSES: Interested persons are 

invited to submit comments regarding 

this proposal. Comments should refer to 

the proposal by name and/or OMB 

Control number and should be sent to: 

Reports Liaison Officer, Office of Policy 

Development and Research, Department 

of Housing and Urban Development, 

451 7th Street, SW., Room 8226, 

Washington, DC 20410–5000. 

FOR FURTHER INFORMATION CONTACT: 

Marina L. Myhre, (202) 708–3700, 

extension 5705 for copies of the 

proposed forms and other available 

documents. (This is not a toll-free 

number.) 

SUPPLEMENTARY INFORMATION: The 

Department will submit the proposed 

information collection to OMB for 

review, as required by the Paperwork 

Reduction Act of 1995 (44 U.S.C. 

Chapter 35, as amended). This Notice is 

soliciting comments from members of 

the public and affected agencies 

concerning the proposed collection of 

information to: (1) Evaluate whether the 

proposed collection of information is 

necessary for the proper performance of 

the functions of the agency, including 

whether the information will have 

practical utility; (2) Evaluate the 

accuracy of the agency’s estimate of the 

burden of the proposed collection of 

information; (3) Enhance the quality, 

utility, and clarity of the information to 

be collected; and (4) Minimize the 

burden of the collection of information 

on those who are to respond, including 

through the use of appropriate 

automated collection techniques or 

other forms of information technology 

(e.g., permitting electronic submission 

of responses). 

This Notice also lists the following 

information: 


sroberts on DSKD5P82C1PROD with NOTICES